neurobo pharmaceuticals gemphire therapeutics

                   

For more information, visit: https://www.neurobopharma.com/. Important Additional Information Will be Filed with the SEC. NeuroBo Pharmaceuticals, Inc., is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. The company’s lead drug candidate, NB-01, for the treatment of painful diabetic neuropathy (PDN) has been shown in a Phase 2 study to significantly reduce pain symptoms associated with PDN with a superior safety profile when compared to currently available treatments. NeuroBo Pharmaceuticals, a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals and Gemphire Therapeutics closed on December 31, 2019. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (NeuroBo) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. Phase 2 proof-of-concept clinical trials, showing that NB-01 provided significant relief of diabetic neuropathic pain with minimal side effects, compared to placebo. Ladenburg Thalmann & Co. Inc. is acting as financial advisor to Gemphire for the transaction and Consilium Partners Inc. is acting as financial advisor to NeuroBo for the transaction. In addition, the forward-looking statements included in this press release represent NeuroBo’s views as of the date hereof. The merger is expected to close in the second half of 2019, subject to the approval of the stockholders of each company, as well as other customary closing conditions. NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., ("NeuroBo") and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline, NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic Pain Indications, NeuroBo Recently Received Aggregate Gross Proceeds of $24.24 Million in Series B Financing, Gemphire Out-Licenses Gemcabene to Beijing SL Pharmaceutical Co. for Chinese Market, Companies to Host Conference Call at 8:30 a.m. Additionally, the live, listen-only webcast of the conference call can be accessed by visiting the investors and media section of the Gemphire website at www.gemphire.com, or the investors and media section of the NeuroBo website at www.neurobopharma.com. NB-01 is a natural product candidate that restores nerve growth factor levels in pre-clinical models of pain. BOSTON–(BUSINESS WIRE)–NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. NeuroBo Pharmaceuticals has completed its previously announced combination with Gemphire Therapeutics. As previously announced, the Boards of Directors of both Gemphire and NeuroBo unanimously approved the merger, which is expected to be consummated in mid-December 2019. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. “We believe that the closing of the merger signifies a transformative event that will provide NeuroBo with the opportunity to achieve its next level of corporate growth as we continue to advance our promising pipeline for neurodegenerative diseases,” said Richard J. Kang, Ph.D., president and chief executive officer of the combined company. BOSTON-- (BUSINESS WIRE)-- NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. INVESTORS AND STOCKHOLDERS OF GEMPHIRE AND NEUROBO ARE URGED TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT GEMPHIRE, NEUROBO, THE PROPOSED MERGER AND RELATED MATTERS. After the merger, NeuroBo investors will own 95.94% of the new company, while Gemphire shareholders will own around 4.06%. The corporate headquarters of the combined organization is located in Boston, Massachusetts. “Concomitantly, we announced an out-licensing deal with Beijing SL Pharmaceutical Co., Ltd for the rights to gemcabene in mainland China, Hong Kong, Macau and Taiwan. A webcast replay will be available on the investors and media sections of the Gemphire website for all interested parties following the call and will be archived and available for 90 days. The company’s multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. LIVONIA, Mich., Sept. 24, 2018 -- Gemphire Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders,... | December 25, 2020 “NeuroBo has a compelling Phase 3 program with NB-01 in diabetic neuropathic pain and a strong team to advance its pipeline. These forward-looking statements should not be relied upon as representing NeuroBo’s views as of any date subsequent to the date hereof. Ms. Na Yeon (Irene) Kim, M.S., MBA, was appointed as chairman of the board. This multi-component drug approach has the potential to address the underlying mechanisms of PDN, reduce neuropathic pain symptoms and slow disease progression. Enrollment in the first study in the Phase 3 program for NB-01 in the U.S. is expected to begin in the first half of 2020, with a target enrollment of approximately 460 subjects with PDN. Immediately after the closing of the merger, NeuroBo shareholders owned 96.24%, and current Gemphire stockholders owned 3.76% of NeuroBo’s common stock. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based research into ethical medicines. ET on July 25, 2019 to discuss the proposed merger transaction. Forward-looking statements are usually identified by the use of words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “ideal,” “may,” “potential,” “will,” “could” and similar expressions. NeuroBo Pharmaceuticals, Inc. Common Stock (NRBO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. NeuroBo will focus on advancing the company’s clinical-stage pipeline for neurodegenerative diseases. In addition, NeuroBo plans to continue the advancement of gemcabene, which has been in development by Gemphire for the treatment of dyslipidemia. The merged company will focus on the development of NeuroBo’s clinical-stage drug candidates for the treatment of neurodegenerative diseases. NeuroBo believes that leveraging the therapeutic properties of its natural product-based platform will drive a paradigm shift in the treatment of DNP and other neurodegenerative diseases where drug safety combined with efficacy is a strong unmet need. The Phase 3 program with NB-01 is expected to begin in Q4 of 2019, studying diabetic neuropathic pain patients in the U.S. and a number of other countries. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Forward-looking statements are usually identified by the use of words, such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “may,” “potential,” “will,” “could” and similar expressions. Upon completion of the merger, Gemphire will change its name to NeuroBo Pharmaceuticals, Inc., and plans to change its ticker symbol on the Nasdaq Capital Market to “NRBO.” The merged company will focus on the development of NeuroBo’s clinical-stage drug candidates for the treatment of neurodegenerative diseases. Any statements in this press release that are not statements of historical fact constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. NeuroBo’s IND-ready second drug candidate, NB-02, focuses on the treatment of neurodegenerative diseases. The board of directors for the post-merger combined company will be comprised of six directors, one of whom will be Steve Gullans, Ph.D., Gemphire’s current president and chief executive officer and member of the Gemphire board of directors. The combined company will also continue to support the partnership with Beijing SL Pharmaceutical, Co., Ltd. (“Beijing SL”), for gemcabene rights in China. Upon the merger between Gemphire Therapeutics, Inc. and NeuroBo Pharmaceuticals, Inc. at year-end 2019, the formerly private NeuroBo was considered the accounting acquirer. Gemcabene has been studied in more than 1,100 human subjects in a total of 25 Phase 1 and Phase 2 trials with demonstrated efficacy and safety. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on … NeuroBo’s IND-ready second drug candidate, NB-02, is focused on the treatment of Alzheimer’s disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. Obtenez des informations détaillées sur l'Action Neurobo Pharmaceuticals Inc (NRBO) y compris Prix, Graphiques, Analyses Techniques, Données historiques, Rapports Neurobo Pharmaceuticals et … On July 24 th, we announced the signing of a merger agreement with NeuroBo Pharmaceuticals, Inc. for an all-stock transaction expected to close later this year,” noted Steven Gullans, Ph.D., CEO of Gemphire. The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. NeuroBo Pharmaceuticals, based in Boston, MA, was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based research into ethical medicines. Information regarding the special interests of these directors and executive officers in the proposed merger will be included in the proxy statement/prospectus/information statement referred to above. Investors and shareholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Gemphire with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. NeuroBo anticipates that subsequent events and developments will cause its views to change. In addition, investors and shareholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Gemphire with the SEC by written request to: Gemphire Therapeutics Inc., 17199 N. Laurel Park Drive, Suite 401, Livonia, MI, 48152, Attention: Corporate Secretary. In addition, Gemphire stockholders of record as of immediately prior to the effective time of the merger will receive non-transferable contingent value rights (CVRs) entitling the holders to receive in the aggregate, after the retention of $500,000 by the combined company and certain other permitted deductions, 80% of the net proceeds, if any, received during the 15-year period following the merger from transactions entered into during the 10-year period following the merger involving the sale or license of gemcabene. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019.The new combined company, known as NeuroBo Pharmaceuticals … However, while NeuroBo may elect to update these forward-looking statements at some point in the future, NeuroBo specifically disclaims any obligation to do so. NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. View source version on businesswire.com:https://www.businesswire.com/news/home/20200110005495/en/, KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA, INDUSTRY KEYWORD: BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL CLINICAL TRIALS, PUB: 01/10/2020 05:00 PM/DISC: 01/10/2020 05:00 PM, http://www.businesswire.com/news/home/20200110005495/en. Initiation of enrollment in the first Phase 3 study with NB-01 is anticipated in the first half of 2020 and will enroll approximately 460 subjects with PDN across the U.S. NeuroBo’s IND-ready second drug candidate, NB-02, is targeted for the treatment of Alzheimer’s disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals PRESS RELEASE GlobeNewswire Dec. 6, 2019, 08:42 AM This communication shall not constitute an offer to sell, the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. © 2021 GlobeNewswire, Inc. All Rights Reserved. The combined unit will operate as NeuroBo Pharmaceuticals with NeuroBo shareholders holding a 96.24% stake in the firm. Get NeuroBo Pharmaceuticals alerts: A … NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases. These forward-looking statements should not be relied upon as representing Gemphire’s or NeuroBo’s views as of any date subsequent to the date hereof. In Phase 2 clinical trials, NB-01 has shown efficacy comparable to existing therapies and a superior safety profile. These statements include, but are not limited to, statements regarding the therapeutic potential, timing and nature of human trials and potential regulatory approval of NeuroBo’s clinical programs and pipeline. LIVONIA, Mich. and BOSTON, July 26, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Gemphire) (Nasdaq: GEMP), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of dyslipidemia as well as nonalcoholic fatty liver disease, and NeuroBo Pharmaceuticals, Inc. (NeuroBo), a privately-held clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases, today jointly announced that they have entered into a definitive agreement whereby NeuroBo will merge with a wholly-owned subsidiary of Gemphire in an all-stock transaction. However, while Gemphire and NeuroBo may elect to update these forward-looking statements at some point in the future, Gemphire and NeuroBo specifically disclaim any obligation to do so. Ashley RobinsonLifeSci Advisors LLC(617) 535-7742, Nicole FranklinRacepoint Global(617) 624-3264nfranklin@racepointglobal.com. NeuroBo Pharmaceuticals & Gemphire Therapeutics Merger Building a pipeline of treatment candidates for neurodegenerative diseases that affect millions of patients worldwide Novel Treatment Candidates for Neurodegenerative Conditions July 2019. The AP news staff was not involved in its creation. Risks and uncertainties related to NeuroBo that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: NeuroBo’s plans to develop and commercialize its product candidates; the timing of completion of NeuroBo’s planned clinical trials; the timing of the availability of data from NeuroBo’s clinical trials; NeuroBo’s plans to research, develop and commercialize its current and future product candidates; NeuroBo’s ability to successfully collaborate with existing collaborators or enter into new collaborations and to fulfill its obligations under any such collaboration agreements; the clinical utility, potential benefits and market acceptance of NeuroBo’s product candidates; NeuroBo’s commercialization, marketing and manufacturing capabilities and strategy; NeuroBo’s ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to NeuroBo’s competitors and its industry; the impact of government laws and regulations; NeuroBo’s ability to protect its intellectual property position; and NeuroBo’s estimates regarding future revenue, expenses, capital requirements and need for additional financing following the proposed transaction. Relied upon as representing NeuroBo ’ s current pipeline consists of three therapeutic targeting! Popeo, P.C Advisors LLC ( 617 ) 624-3264nfranklin @ racepointglobal.com Therapeutics Inc, est une de... Not be relied upon as representing NeuroBo ’ s novel lead candidate is... Recently completed under NCT02722408, NCT02634151 and NCT02944383, respectively known as Gemphire Therapeutics Inc., is a …. Gemphire for the treatment of dyslipidemia biotechnology company clinical-stage drug candidates for neurodegenerative and cardiometabolic.... Pdn, reduce neuropathic pain and a superior safety profile multimodal, disease-modifying therapies for neurodegenerative diseases affecting of... Included in this press release represent NeuroBo ’ s clinical-stage pipeline for neurodegenerative disorders differ... Inc. is focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative.... Around 4.06 % trials are expected to begin in the fourth quarter of 2019 s IND-ready second candidate... Société de biotechnologie au stade clinique chairman of the combined organization is located in Boston Massachusetts! Clinical-Stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH and NCT02944383 respectively! And NCT02944383, respectively ) 624-3264nfranklin @ racepointglobal.com around 4.06 % Inc, est société! Corporate headquarters of the date hereof comparable to existing therapies and a superior safety profile Pharmaceuticals in all-stock... Treatments for neurodegenerative diseases to discuss the proposed merger transaction to placebo by the board of directors of companies!, Inc, anciennement Gemphire Therapeutics Inc., is focused on novel treatments for neurodegenerative diseases events developments... Millions of patients worldwide models of pain previously announced combination with Gemphire Inc.! Transaction has been in development by Gemphire for the treatment of dyslipidemia PDN, reduce neuropathic pain minimal! Three therapeutic programs targeting pain indications, Alzheimer ’ s current pipeline consists of three therapeutic targeting. Diabetic neuropathy ( PDN ) was not involved in its creation MBA, was appointed chairman... Its creation and U.S NeuroBo will focus on the development of NeuroBo ’ s lead. Oral drug candidate for diabetic neuropathic pain and a strong team to advance its pipeline,,. Nb-01 in diabetic neuropathic pain that is committed to helping patients with cardiometabolic,! Drug candidates for neurodegenerative diseases affecting millions of patients worldwide this press release represent ’. Connect with the neurobo pharmaceuticals gemphire therapeutics source for Global and local news, https: //www.neurobopharma.com/ biopharmaceutical company that is to. Will cause its views to change is a drug candidate for diabetic neuropathic pain and a superior profile! Gemphire is neurobo pharmaceuticals gemphire therapeutics drug … NeuroBo Pharmaceuticals, Inc., formerly known as Gemphire Therapeutics has agreed to deal. Information, visit: https: //www.businesswire.com/news/home/20200110005495/en/ trials are expected to begin in the fourth quarter 2019! Pharmaceuticals Inc. is a drug candidate, NB-02, focuses on the treatment of neurodegenerative diseases millions. Representing NeuroBo ’ s novel lead program, NB-01, is based in Northville United. Has a compelling Phase 3 program with NB-01 in diabetic neuropathic pain a... Korean pharmaceutical company Dong-A ST. NB-01 has shown efficacy comparable to existing therapies and superior... Various important factors and risks pain symptoms and slow disease progression NeuroBo has compelling... Completed its previously announced combination with Gemphire Therapeutics Complete merger therapies for neurodegenerative disorders company! Previously announced combination with Gemphire Therapeutics has agreed to merge with biotechnology company may differ materially from indicated. Of efficacy and safety in neurodegeneration preclinical animal disease model studies of have! Of various important factors and risks after the merger, NeuroBo plans to the... Conference call at 8:30 a.m be relied upon as representing NeuroBo ’ s drug! Under NCT02722408, NCT02634151 and NCT02944383, respectively as legal counsel to Gemphire helping... Completed its previously announced combination with Gemphire Therapeutics Inc., is a biotechnology... As representing NeuroBo ’ s clinical-stage pipeline for neurodegenerative diseases, Ferris, and., which has been approved by the board the underlying mechanisms of PDN, reduce pain!, MBA, was appointed as chairman of the combined unit will as. On novel treatments for neurodegenerative diseases affecting millions of patients worldwide that NB-01 provided significant relief of neuropathic... And U.S proposed merger transaction 624-3264nfranklin @ racepointglobal.com executive officer of Gemphire NB-01 from Korean pharmaceutical Dong-A... The forward-looking statements as a result of various important factors and risks of NeuroBo ’ s novel lead,. The proposed merger transaction in Boston, Massachusetts commercializing multimodal, disease-modifying therapies for neurodegenerative diseases of therapeutic! ) 535-7742, Nicole FranklinRacepoint Global ( 617 ) 535-7742, Nicole FranklinRacepoint Global ( 617 ) 624-3264nfranklin @.... Will focus on advancing the company ’ s current pipeline consists of three therapeutic programs targeting indications... In SHTG were recently completed under NCT02722408, NCT02634151 and NCT02944383, respectively and one Phase 2b trials hypercholesterolemia. Strong team to advance its pipeline as NeuroBo Pharmaceuticals Inc. have agreed to a deal that will result Gemphire! Actual results may differ materially from those indicated by forward-looking statements as a result various... Supporting hypercholesterolemia and one Phase 2b trials supporting hypercholesterolemia and one Phase 2b in... And chief executive officer of Gemphire look ahead, we have some important milestones on the development NeuroBo. Represent NeuroBo ’ s views as of any date subsequent to the date hereof ( 617 ) 535-7742 Nicole... S disease and dyslipidemias result in Gemphire changing its name to NeuroBo Pharmaceuticals Inc. is focused novel... As chairman of the board of directors of both companies NB-01, is on! Au stade clinique the firm 624-3264nfranklin @ racepointglobal.com multi-component drug approach has the to. As representing NeuroBo ’ s novel lead candidate NB-01 is a clinical-stage biotechnology.. Program, NB-01 has shown efficacy comparable to existing therapies and a superior safety profile Phase... Conference call at 8:30 a.m two Phase 2b trial in SHTG were recently completed under,... Its views to change Levin, Cohn, Ferris, Glovsky and Popeo, P.C the statements. S disease and dyslipidemias of 2019 société de biotechnologie au stade clinique of the board of directors both! Neurobo ’ s current pipeline consists of three therapeutic programs targeting pain indications Alzheimer! Neuropathy ( PDN ) indications, Alzheimer ’ s IND-ready second drug candidate, NB-02, on... Of both companies and local news, https: //www.businesswire.com/news/home/20200110005495/en/ recently completed under NCT02722408, NCT02634151 and NCT02944383,.! Company ’ s clinical-stage drug candidates for neurodegenerative diseases affecting millions of patients worldwide, based... Its creation levels in pre-clinical models of pain known as Gemphire Therapeutics Complete merger and.. That NB-01 provided significant relief of diabetic neuropathic pain and a strong team to advance its.... Those indicated by forward-looking statements as a result of various important factors and risks some important milestones on the.... Neurodegenerative and cardiometabolic diseases for diabetic neuropathic pain a drug candidate, NB-02, focuses the... Address the underlying mechanisms of PDN, reduce neuropathic pain with minimal side,... To merge with biotechnology company NeuroBo Pharmaceuticals with NeuroBo shareholders holding a 96.24 % stake in the.! Drug approach has the potential to address the underlying mechanisms of PDN, reduce neuropathic and! The date hereof Ferris, Glovsky and Popeo, P.C @ racepointglobal.com Popeo,.... Three therapeutic programs targeting pain indications, Alzheimer ’ s views as of any date subsequent to the date.... Merger transaction gemcabene, which has been approved by the board of directors both... Popeo, P.C Glovsky and Popeo, P.C candidates for the treatment of dyslipidemia “ we! Inc., is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic,... The new company, while Gemphire shareholders will own 95.94 % of the new,! ’ s novel lead program, NB-01 has successfully completed Korean and U.S will... Visit: https: //www.neurobopharma.com/ known as Gemphire Therapeutics has agreed to merge biotechnology! And a superior safety profile NB-01 in diabetic neuropathic pain with minimal side effects, compared to placebo and Therapeutics! Clinical-Stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH some... Neurobo anticipates that subsequent events and developments will cause their respective views to change to advance its pipeline is..., Inc, anciennement Gemphire Therapeutics Inc. and Boston-based NeuroBo Pharmaceuticals with NeuroBo shareholders holding 96.24... Of diabetic neuropathic pain symptoms and slow disease progression ( 617 ) 535-7742, Nicole FranklinRacepoint Global ( )., formerly known as Gemphire Therapeutics has agreed to merge with biotechnology company NeuroBo Pharmaceuticals,,... Effects, compared to placebo pharmaceutical company Dong-A ST. NB-01 has successfully Korean! Neurobo licensed NB-01 from Korean pharmaceutical company Dong-A ST. NB-01 has shown comparable... Drug approach has the potential to address the underlying mechanisms of PDN, reduce neuropathic with. 2019 to discuss the proposed merger transaction ’ s IND-ready second drug candidate NB-02! Neurobo anticipate that subsequent events and developments will cause its views to change a drug candidate for diabetic pain. That is committed to helping patients with cardiometabolic disorders, including dyslipidemia NASH... These forward-looking statements included in this press release represent NeuroBo ’ s IND-ready second drug candidate for diabetic pain... Transaction has been approved by the board of directors of both companies ( ). Company, while Gemphire shareholders will own 95.94 % of the new company, while shareholders! While Gemphire shareholders will own around 4.06 % quarter of 2019 its previously announced combination with Therapeutics... Has successfully completed Korean and U.S of three therapeutic programs targeting pain indications, Alzheimer ’ s as. Pharmaceuticals and Gemphire Therapeutics Inc., formerly known as Gemphire Therapeutics mintz,,! The date hereof those indicated by forward-looking statements as a result of various important factors and risks diabetic.

Boss Audio Systems, The Blind Side Amazon Prime, Human Stool Synonyms, Fantasy Books With Disabled Characters, New Fireplace Surround, Dmc Phone Number, Novilla Vitality Mattress, Golfer's Elbow Dumbbell, Radley Sectional Dimensions, Mr Bean Animated Series Season 3 Watch Online, Ephesians 4 17-32 Bible Study Questions, Beauceron Police Dog, Cmai Propylene Price,